APPLICATION
ANDA207381
TYPE
ANDA
ORIGINAL APPROVAL
2023-07-05
LATEST ACTION
2023-07-05
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued
Products
CABAZITAXELDiscontinued
CABAZITAXEL 60MG/1.5ML (40MG/ML) · SOLUTION · INTRAVENOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.